BioSyent Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOYF research report →
Companywww.biosyent.com
BioSyent Inc. , a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia.
- CEO
- René C. Goehrum
- IPO
- 2012
- Employees
- 60
- HQ
- Mississauga, ON, CA
Price Chart
Valuation
- Market Cap
- $117.27M
- P/E
- 17.56
- P/S
- 3.50
- P/B
- 3.53
- EV/EBITDA
- 12.21
- Div Yield
- 1.46%
Profitability
- Gross Margin
- 74.11%
- Op Margin
- 25.10%
- Net Margin
- 19.65%
- ROE
- 22.05%
- ROIC
- 17.03%
Growth & Income
- Revenue
- $43.02M · 22.80%
- Net Income
- $9.00M · 23.86%
- EPS
- $0.80 · 25.00%
- Op Income
- $11.30M
- FCF YoY
- 139.31%
Performance & Tape
- 52W High
- $12.00
- 52W Low
- $7.63
- 50D MA
- $10.79
- 200D MA
- $9.38
- Beta
- 0.50
- Avg Volume
- 1.97K
Get TickerSpark's AI analysis on BIOYF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BIOYF Coverage
We haven't published any research on BIOYF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BIOYF Report →